Takeyama M, Ikawa K, Eto I, Mori K
Department of Clinical Pharmacy, Oita Medical University, Japan.
Biol Pharm Bull. 1995 Jun;18(6):900-2. doi: 10.1248/bpb.18.900.
A sensitive and specific double-antibody enzyme immunoassay (EIA) for detecting an elcatonin-like immunoreactive substance (ECT-IS) in human plasma has been developed. In competitive reactions, the ECT antibody was incubated with a plasma sample (or ECT standard) and beta-D-galactosidase-linked synthetic ECT. Free and antibody-bound enzymes were separated using an anti-rabbit IgG-coated immunoplate. Enzyme activity on the plate was determined by fluorescence analysis. This immunoassay allows the detection of 20 to 300 fmol/ml (67 to 1000 pg/ml) of ECT. The EIA was applied to determine the pharmacokinetic behavior of ECT after a single intramuscular administration (20 IU). The maximum level was achieved 30 min after administration, at approximately 30 pg ECT/ml of plasma.
已开发出一种灵敏且特异的双抗体酶免疫测定法（EIA），用于检测人血浆中一种降钙素基因相关肽样免疫反应性物质（ECT - IS）。在竞争性反应中，将ECT抗体与血浆样本（或ECT标准品）以及β - D - 半乳糖苷酶连接的合成ECT一起孵育。使用抗兔IgG包被的免疫板分离游离酶和与抗体结合的酶。通过荧光分析测定板上的酶活性。这种免疫测定法能够检测到20至300飞摩尔/毫升（67至1000皮克/毫升）的ECT。该EIA被用于测定单次肌肉注射（20国际单位）后ECT的药代动力学行为。给药后30分钟达到最高水平，血浆中约为30皮克ECT/毫升。
